Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nano-selenium plus Xuebijing in ICU patients with sepsis
ChiCTR2300072222Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Jinan University
- Start
- Jun 2023
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial in sepsis comparing Nano-selenium plus Xuebijing with Xuebijing alone (2 arms). Primary endpoints: Inflammatory biomarkers, Immune function and 1 more. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
nanoseleniumxuebijing
03
Conditions
sepsis
Beyond the preview
Go deeper on ChiCTR2300072222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072222.